Demographic and regional trends in systemic and cardiovascular amyloidosis-related mortality among older adults in the United States from 1999 to 2020
Authors:
- 20 February 2025
- journal article
- research article
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 20 (4) , 1003-1012
Abstract
Despite therapy advancements, amyloidosis mortality rates for older adults (aged ≥ 65) are rising. This study analyzes trends in amyloidosis-related mortality among older adults in the U.S. We conducted a cross-sectional analysis of death certificates from the CDC WONDER database for amyloidosis-related deaths from 1999 to 2020. Age-adjusted mortality rates (AAMRs) per 100,000 persons and annual percent change (APC) were calculated by age, race/ethnicity, urban–rural classification, and region. From 1999 to 2020, AAMR for amyloidosis in older adults (aged ≥ 65) in the U.S. increased from 2.7 to 5.6. Men consistently had higher AAMRs than women (men: 3.7 vs. women: 2.2 in 1999; men: 8.5 vs. women: 3.5 in 2020). In 2020, Non-Hispanic Blacks had the highest AAMR at 11.8, with an APC of 19.8 (95% CI 10.5–25.5). Regional differences were notable, with AAMRs highest in the Northeast (6.9) and lowest in the South (4.2). Large metropolitan areas had a higher AAMR (6.3) than non-metropolitan areas (4.6). Cardiac amyloidosis accounted for 68.8% of deaths, with AAMR rising from 1.7 to 4.2. There has been a significant increase in AAMRs for amyloidosis in the U.S. from 1999 to 2020, particularly among males, Non-Hispanic Blacks, and those in large metropolitan and Northeast areas. These findings stress the need for enhanced prevention and treatment strategies for older adults. Graphical abstractKeywords
This publication has 35 references indexed in Scilit:
- Current Therapies and Future Horizons in Cardiac Amyloidosis TreatmentCurrent Heart Failure Reports, 2024
- Disease features and management of cardiomyopathies in womenHeart Failure Reviews, 2024
- Patiromer use in patients with heart failure: lessons and clinical considerations from the DIAMOND trialEuropean Journal of Heart Failure, 2022
- Association of Transthyretin Val122Ile Variant With Incident Heart Failure Among Black IndividualsJAMA, 2022
- Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internistInternal and Emergency Medicine, 2022
- Development of a conceptual model of patient-reported outcomes in light chain amyloidosis: a qualitative studyQuality of Life Research, 2021
- Transthyretin Cardiac Amyloidosis: An Update on Diagnosis and TreatmentESC Heart Failure, 2019
- Cardiac amyloidosis: the need for early diagnosisNetherlands Heart Journal, 2019
- When and how do patients with cardiac amyloidosis die?Clinical Research in Cardiology, 2019
- Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015JAMA Cardiology, 2018